Marksans Pharma Financial Statements
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
| Y/e 31 Mar | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
| Growth matrix (%) | ||||
| Revenue growth | 24.30 | 19 | (14) | 12.10 |
| Op profit growth | 122 | 93.30 | (67) | (26) |
| EBIT growth | 176 | 177 | (81) | (32) |
| Net profit growth | 255 | 273 | (89) | (28) |
| Profitability ratios (%) | ||||
| OPM | 17 | 9.48 | 5.83 | 15.30 |
| EBIT margin | 14.60 | 6.58 | 2.83 | 13.10 |
| Net profit margin | 10.30 | 3.61 | 1.15 | 8.79 |
| RoCE | 25.80 | 10.30 | 3.91 | 22.70 |
| RoNW | 5.29 | 1.82 | 0.50 | 4.71 |
| RoA | 4.55 | 1.42 | 0.40 | 3.80 |
| Per share ratios () | ||||
| EPS | 2.95 | 0.87 | -- | 1.99 |
| Dividend per share | 0.10 | 0.05 | 0.05 | 0.41 |
| Cash EPS | 2.21 | 0.15 | (0.50) | 1.23 |
| Book value per share | 15.50 | 11.50 | 10.60 | 11.10 |
| Valuation ratios | ||||
| P/E | 4.71 | 36.40 | -- | 23.20 |
| P/CEPS | 6.30 | 212 | (91) | 37.50 |
| P/B | 0.89 | 2.75 | 4.45 | 4.28 |
| EV/EBIDTA | 2.57 | 15.80 | 38.90 | 13.40 |
| Payout (%) | ||||
| Dividend payout | -- | 7.49 | 193 | 22.90 |
| Tax payout | (23) | (28) | (24) | (23) |
| Liquidity ratios | ||||
| Debtor days | 67.60 | 84.90 | 111 | 81.90 |
| Inventory days | 74 | 81.60 | 85.10 | 60.90 |
| Creditor days | (35) | (53) | (71) | (54) |
| Leverage ratios | ||||
| Interest coverage | (19) | (5.90) | (3.20) | (12) |
| Net debt / equity | (0.10) | 0.17 | 0.20 | 0.12 |
| Net debt / op. profit | (0.40) | 0.90 | 1.89 | 0.39 |
| Cost breakup () | ||||
| Material costs | (48) | (57) | (60) | (57) |
| Employee costs | (15) | (16) | (20) | (14) |
| Other costs | (20) | (17) | (15) | (14) |
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
| Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
| Revenue | 1,134 | 913 | 767 | 893 |
| yoy growth (%) | 24.30 | 19 | (14) | 12.10 |
| Raw materials | (545) | (523) | (459) | (510) |
| As % of sales | 48 | 57.30 | 59.80 | 57.10 |
| Employee costs | (168) | (148) | (150) | (122) |
| As % of sales | 14.80 | 16.20 | 19.50 | 13.70 |
| Other costs | (229) | (155) | (114) | (125) |
| As % of sales | 20.20 | 17 | 14.90 | 14 |
| Operating profit | 192 | 86.50 | 44.70 | 136 |
| OPM | 17 | 9.48 | 5.83 | 15.30 |
| Depreciation | (27) | (27) | (30) | (28) |
| Interest expense | (8.70) | (10) | (6.80) | (10) |
| Other income | 0.33 | 0.36 | 7.02 | 8.87 |
| Profit before tax | 157 | 49.80 | 14.90 | 107 |
| Taxes | (36) | (14) | (3.60) | (24) |
| Tax rate | (23) | (28) | (24) | (23) |
| Minorities and other | (3.70) | (2.90) | (2.50) | (4.20) |
| Adj. profit | 117 | 32.90 | 8.84 | 78.50 |
| Exceptional items | -- | -- | -- | -- |
| Net profit | 117 | 32.90 | 8.84 | 78.50 |
| yoy growth (%) | 255 | 273 | (89) | (28) |
| NPM | 10.30 | 3.61 | 1.15 | 8.79 |
- Switch to
-
Tabular DataGraph
| Y/e 31 Mar ( In .Cr) | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
| Profit before tax | 157 | 49.80 | 14.90 | 107 |
| Depreciation | (27) | (27) | (30) | (28) |
| Tax paid | (36) | (14) | (3.60) | (24) |
| Working capital | 584 | 474 | 196 | 105 |
| Other operating items | -- | -- | -- | -- |
| Operating cashflow | 678 | 483 | 177 | 159 |
| Capital expenditure | 225 | 245 | 200 | 168 |
| Free cash flow | 903 | 728 | 377 | 327 |
| Equity raised | 353 | 171 | 409 | 431 |
| Investments | -- | -- | -- | -- |
| Debt financing/disposal | (116) | (61) | (53) | 139 |
| Dividends paid | -- | 2.05 | 2.05 | 16.80 |
| Other items | -- | -- | -- | -- |
| Net in cash | 1,140 | 840 | 735 | 914 |
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
| Y/e 31 Mar ( In .Cr) | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
| Equity capital | 40.90 | 40.90 | 40.90 | 40.90 |
| Preference capital | -- | -- | -- | -- |
| Reserves | 595 | 502 | 430 | 393 |
| Net worth | 636 | 542 | 471 | 433 |
| Minority interest | ||||
| Debt | 18.90 | 100 | 118 | 110 |
| Deferred tax liabilities (net) | 13.40 | 8.56 | 7.57 | 6.75 |
| Total liabilities | 681 | 661 | 606 | 556 |
| Fixed assets | 303 | 270 | 279 | 267 |
| Intangible assets | ||||
| Investments | -- | -- | -- | -- |
| Deferred tax asset (net) | 3.20 | 2.78 | 3.01 | 2.64 |
| Net working capital | 282 | 355 | 284 | 261 |
| Inventories | 242 | 293 | 218 | 190 |
| Inventory Days | 77.80 | -- | 87.20 | 90.40 |
| Sundry debtors | 243 | 177 | 177 | 248 |
| Debtor days | 78.30 | -- | 70.70 | 118 |
| Other current assets | 14.60 | 29.40 | 16.50 | 21.70 |
| Sundry creditors | (105) | (106) | (78) | (162) |
| Creditor days | 33.60 | -- | 31.10 | 77 |
| Other current liabilities | (114) | (38) | (50) | (37) |
| Cash | 93.70 | 33.50 | 39.90 | 25.20 |
| Total assets | 681 | 661 | 606 | 556 |
- Switch to
-
ConsolidatedStandalone
| Particulars ( Rupees In Crores.) | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 |
|---|---|---|---|---|---|
| Gross Sales | 799 | 753 | 713 | 582 | 683 |
| Excise Duty | -- | -- | -- | -- | -- |
| Net Sales | 799 | 753 | 713 | 582 | 683 |
| Other Operating Income | -- | -- | -- | -- | 2.42 |
| Other Income | 0.30 | 0.18 | 0.43 | 6.72 | -- |
| Total Income | 799 | 753 | 714 | 589 | 686 |
| Total Expenditure ** | 676 | 641 | 631 | 542 | 551 |
| PBIDT | 123 | 111 | 82.90 | 47.20 | 134 |
| Interest | 6.71 | 7.22 | 6.74 | 4.16 | 8.19 |
| PBDT | 117 | 104 | 76.10 | 43 | 126 |
| Depreciation | 17 | 16.50 | 20.70 | 22.60 | 19.80 |
| Minority Interest Before NP | -- | -- | -- | -- | -- |
| Tax | 20.40 | 16.80 | 12.70 | 1.67 | 19.70 |
| Deferred Tax | 1.19 | 0.25 | 0.52 | 1.23 | -- |
| Reported Profit After Tax | 78 | 70.60 | 42.30 | 17.60 | 86.70 |
| Minority Interest After NP | -- | -- | 2.46 | 2.48 | 2.42 |
| Net Profit after Minority Interest | 78 | 70.60 | 39.80 | 15.10 | 84.30 |
| Extra-ordinary Items | -- | -- | -- | -- | -- |
| Adjusted Profit After Extra-ordinary item | 78 | 70.60 | 39.80 | 15.10 | 84.30 |
| EPS (Unit Curr.) | 1.86 | 1.66 | 0.97 | 0.31 | 2.06 |
| Book Value (Unit Curr.) | -- | -- | -- | -- | -- |
| Dividend (%) | -- | -- | -- | -- | -- |
| Equity | 40.90 | 40.90 | 40.90 | 40.90 | 40.90 |
| Public Shareholding (Number) | -- | -- | -- | -- | -- |
| Public Shareholding (%) | -- | -- | -- | -- | -- |
| Pledged/Encumbered - No. of Shares | -- | -- | -- | -- | -- |
| Pledged/Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | -- |
| Pledged/Encumbered - % in Total Equity | -- | -- | -- | -- | -- |
| Non Encumbered - No. of Shares | -- | -- | -- | -- | -- |
| Non Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | -- |
| Non Encumbered - % in Total Equity | -- | -- | -- | -- | -- |
| PBIDTM(%) | 15.40 | 14.80 | 11.60 | 8.10 | 19.70 |
| PBDTM(%) | 14.60 | 13.80 | 10.70 | 7.38 | 18.50 |
| PATM(%) | 9.77 | 9.38 | 5.93 | 3.01 | 12.70 |
